Form 8-K - Current report:
SEC Accession No. 0001829126-25-000905
Filing Date
2025-02-12
Accepted
2025-02-12 16:08:55
Documents
23
Period of Report
2025-02-06
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cyclacel_8k.htm   iXBRL 8-K 41449
2 EXHIBIT 3.2 cyclacel_ex3-2.htm EX-3.2 105414
3 EXHIBIT 3.4 cyclacel_ex3-4.htm EX-3.4 82898
4 EXHIBIT 3.5 cyclacel_ex3-5.htm EX-3.5 12543
5 GRAPHIC ex3-2_002.jpg GRAPHIC 5407
6 GRAPHIC ex3-2_001.jpg GRAPHIC 42788
7 GRAPHIC ex3-4_002.jpg GRAPHIC 5407
8 GRAPHIC ex3-4_001.jpg GRAPHIC 6377
9 GRAPHIC ex3-5_002.jpg GRAPHIC 5407
10 GRAPHIC ex3-5_001.jpg GRAPHIC 42788
  Complete submission text file 0001829126-25-000905.txt   659343

Data Files

Seq Description Document Type Size
11 XBRL SCHEMA FILE cycc-20250206.xsd EX-101.SCH 3744
12 XBRL DEFINITION FILE cycc-20250206_def.xml EX-101.DEF 26582
13 XBRL LABEL FILE cycc-20250206_lab.xml EX-101.LAB 36614
14 XBRL PRESENTATION FILE cycc-20250206_pre.xml EX-101.PRE 25206
25 EXTRACTED XBRL INSTANCE DOCUMENT cyclacel_8k_htm.xml XML 5742
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50626 | Film No.: 25614854
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)